Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 16/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13534002 | 0.87 | OPRM1 (0.52) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL21874409 | 0.85 | OPRM1 (0.50) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL13317183 | 0.83 | OPRM1 (0.58) | OPRM1SIGMAR1OPRD1OPRK1KCNH2 | |
| SCHEMBL6045452 | 0.82 | OPRM1 (0.62) | OPRM1SIGMAR1OPRD1OPRK1 | |
| SCHEMBL13451313 | 0.81 | CACNA1C (0.71) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL13526102 | 0.81 | OPRM1 (0.61) | OPRM1SIGMAR1OPRD1OPRK1KCNH2 | |
| SCHEMBL14355475 | 0.81 | CACNA1C (0.58) | OPRM1OPRD1OPRK1OPRL1 | |
| Oxalic Acid SCHEMBL6045520 | 0.79 | OPRM1 (0.54) | OPRM1SIGMAR1OPRD1OPRK1KCNH2 | |
| SCHEMBL593749 | 0.79 | SIGMAR1 (0.50) | OPRM1SIGMAR1OPRD1KCNH2ACHE | |
| SCHEMBL2331319 | 0.78 | OPRM1 (0.61) | OPRM1SIGMAR1ACHEOPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1559428-A1 | RECEPTOR REGULATOR | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | NMUR1, NMUR2, NMBR | OPRM1 148/4885SIGMAR1 179/4885OPRD1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.